crn04894
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Dec 18, 2020 (NCT06048887)
Timeline
Indications
Mechanism of action
- Melanocortin receptor 2ANTAGONIST
MC2R antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1ccccc1-c1ccc(N2CCN(C(=O)C3(C(F)(F)F)CCC3)C[C@H]2CC)c(C(=O)N[C@@H]2CN3CCC2CC3)n1- Mol. weight
- 613.73 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5414447 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07159841 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2025 | Crinetics Pharmaceuticals Inc. |
| NCT07221084 | Phase 1 | Oct 31, 2025 | Crinetics Pharmaceuticals Inc. |
| NCT07144163 | Phase 3 | Sep 30, 2025 | Crinetics Pharmaceuticals Inc. |
| NCT06712823 | Phase 2 | Nov 30, 2024 | Crinetics Pharmaceuticals Inc. |
| NCT05804669 | Phase 1/Phase 2 (Phase 2) | Oct 12, 2023 | Crinetics Pharmaceuticals Inc. |
| NCT05907291 | Phase 2 | Jul 3, 2023 | Crinetics Pharmaceuticals Inc. |
| NCT06048887 | Phase 1 | Dec 18, 2020 | Crinetics Pharmaceuticals Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Crinetics Pharmaceuticals Inc. | For profit | 7 | 7 | 3 | 2020 |
1 organizations
Page 1 / 1